These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 21556211)

  • 21. Whole blood selenium levels (WBSL) in patients with prostate cancer (PC), benign prostatic hyperplasia (BPH) and healthy male inhabitants (HMI) and prostatic tissue selenium levels (PTSL) in patients with PC and BPH.
    Muecke R; Klotz T; Giedl J; Buentzel J; Kundt G; Kisters K; Prott FJ; Micke O
    Acta Oncol; 2009; 48(3):452-6. PubMed ID: 18855158
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of cyclooxygenase-2 in prostate carcinoma.
    Yoshimura R; Sano H; Masuda C; Kawamura M; Tsubouchi Y; Chargui J; Yoshimura N; Hla T; Wada S
    Cancer; 2000 Aug; 89(3):589-96. PubMed ID: 10931458
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of the inflammatory network in benign prostate hyperplasia and prostate cancer.
    König JE; Senge T; Allhoff EP; König W
    Prostate; 2004 Feb; 58(2):121-9. PubMed ID: 14716737
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prostate growth and inflammation.
    Sciarra A; Mariotti G; Salciccia S; Autran Gomez A; Monti S; Toscano V; Di Silverio F
    J Steroid Biochem Mol Biol; 2008 Feb; 108(3-5):254-60. PubMed ID: 17935971
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inflammation and chronic prostatic diseases: evidence for a link?
    Sciarra A; Di Silverio F; Salciccia S; Autran Gomez AM; Gentilucci A; Gentile V
    Eur Urol; 2007 Oct; 52(4):964-72. PubMed ID: 17618043
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dynamic contrast-enhanced MRI of benign prostatic hyperplasia and prostatic carcinoma: correlation with angiogenesis.
    Ren J; Huan Y; Wang H; Chang YJ; Zhao HT; Ge YL; Liu Y; Yang Y
    Clin Radiol; 2008 Feb; 63(2):153-9. PubMed ID: 18194690
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Apoptosis profiles in benign prostatic hyperplasia: close associations of cell kinetics with percent area density of histologic composition.
    Zhang X; Zhang Q; Zhang Z; Na Y; Guo Y
    Urology; 2006 Oct; 68(4):905-10. PubMed ID: 17070390
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
    Ho PJ; Baxter RC
    Clin Endocrinol (Oxf); 1997 Mar; 46(3):333-42. PubMed ID: 9156044
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Apoptotic versus proliferative activities in human benign prostatic hyperplasia.
    Kyprianou N; Tu H; Jacobs SC
    Hum Pathol; 1996 Jul; 27(7):668-75. PubMed ID: 8698310
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Apoptosis-related gene expression in benign prostatic hyperplasia and prostate carcinoma.
    Iacopino F; Angelucci C; Lama G; Zelano G; La Torre G; D'Addessi A; Giovannini C; Bertaccini A; Macaluso MP; Martorana G; Sica G
    Anticancer Res; 2006; 26(3A):1849-54. PubMed ID: 16827116
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential response to zinc-induced apoptosis in benign prostate hyperplasia and prostate cancer cells.
    Yan M; Hardin K; Ho E
    J Nutr Biochem; 2010 Aug; 21(8):687-94. PubMed ID: 19576751
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2.
    Hsu AL; Ching TT; Wang DS; Song X; Rangnekar VM; Chen CS
    J Biol Chem; 2000 Apr; 275(15):11397-403. PubMed ID: 10753955
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression analysis of peptide growth factors VEGF, FGF2, TGFB1, EGF and IGF1 in prostate cancer and benign prostatic hyperplasia.
    Soulitzis N; Karyotis I; Delakas D; Spandidos DA
    Int J Oncol; 2006 Aug; 29(2):305-14. PubMed ID: 16820871
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of gold nanoparticles treatment on the testosterone-induced benign prostatic hyperplasia in rats.
    Al-Trad B; Aljabali A; Al Zoubi M; Shehab M; Omari S
    Int J Nanomedicine; 2019; 14():3145-3154. PubMed ID: 31118628
    [No Abstract]   [Full Text] [Related]  

  • 35. Overexpression of cysteinyl LT1 receptor in prostate cancer and CysLT1R antagonist inhibits prostate cancer cell growth through apoptosis.
    Matsuyama M; Hayama T; Funao K; Kawahito Y; Sano H; Takemoto Y; Nakatani T; Yoshimura R
    Oncol Rep; 2007 Jul; 18(1):99-104. PubMed ID: 17549353
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The angiotensin converting enzyme inhibitor captopril attenuates testosterone-induced benign prostatic hyperplasia in rats; a mechanistic approach.
    Mostafa F; Mantawy EM; Azab SS; El-Demerdash E
    Eur J Pharmacol; 2019 Dec; 865():172729. PubMed ID: 31605676
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Amelioration of testosterone-induced benign prostatic hyperplasia using febuxostat in rats: The role of VEGF/TGFβ and iNOS/COX-2.
    Abdel-Aziz AM; Gamal El-Tahawy NF; Salah Abdel Haleem MA; Mohammed MM; Ali AI; Ibrahim YF
    Eur J Pharmacol; 2020 Dec; 889():173631. PubMed ID: 33031799
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BCL-2 and BCL-XL expression are down-regulated in benign prostate hyperplasia nodules and not affected by finasteride and/or celecoxib.
    Li F; Pascal LE; Zhou J; Zhou Y; Wang K; Parwani AV; Dhir R; Guo P; He D; Nelson JB; Wang Z
    Am J Clin Exp Urol; 2018; 6(1):1-10. PubMed ID: 29531971
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased COX-1 expression in benign prostate epithelial cells is triggered by mitochondrial dysfunction.
    Hudson CN; He K; Pascal LE; Liu T; Myklebust LK; Dhir R; Srivastava P; Yoshimura N; Wang Z; Ricke WA; DeFranco DB
    Am J Clin Exp Urol; 2022; 10(4):234-245. PubMed ID: 36051613
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Diffusion weighted MRI helps evaluate angiogenesis and vascular endothelial growth factor expression in prostate cancer].
    Liu JG; Wang B; Wang XZ; Niu QL; Zhang Q
    Zhonghua Nan Ke Xue; 2009 May; 15(5):403-8. PubMed ID: 19514550
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.